Bumetanide to treat autism spectrum disorders: are complex administrative regulations fit to treat heterogeneous disorders?

Abstract

Introduction: Extensive experimental observations suggest that the regulation of ion fluxes and, notably, chloride are impacted in autism spectrum disorders (ASD) and other neurodevelopmental disorders. The specific NKCC1 cotransporter inhibitor Bumetanide has been shown to attenuate electrophysiological and behavioral features of ASD in experimental models. Both pilot and phase 2 double-blind randomized independent trials have validated these effects with thousands of children treated successfully. Both brain imaging and eye tracking observations also validate these observations. However, final large phase 3 trials failed, with no significant differences between placebo and treated children.

Methods: Here, I discuss the possible reasons for these failures and discuss the exclusive reliance on complex patent cooperation Treaty (PCT) regulations. Indeed, available data suggest that bumetanide responders could be identified by relying notably on EEG measures, suggesting that biological sub-populations of patients might benefit from the treatment.

Results: These observations raise important debates on whether treating only a % of children with ASD is acceptable.

Discussion: It is likely that in many disorders, the heterogeneity of the pathological event precludes a single general treatment for all, suggesting that trials centered on selective populations of responders might be essential for large clinical trials to succeed.

Keywords

Autism spectrum disorders / brain imaging / eye tracking

References

[1] Ben-Ari Y,Corradetti R.Giant synaptic potentials in immature rat CA3 hippocampal neurones.J Physiol1989;416:303-25 PMCID:PMC1189216

[2] Ben-ari Y,Raggozzino D,Gaiarsa J.γ-Aminobutyric acid (GABA): a fast excitatory transmitter which may regulate the development of hippocampal neurones in early postnatal life.Prog Brain Res1994;102:261-73.

[3] Ben-Ari Y.Excitatory actions of gaba during development: the nature of the nurture.Nat Rev Neurosci2002;3:728-39

[4] Ben-Ari Y.The GABA excitatory/inhibitory developmental sequence: a personal journey.Neurosci2014;279:187-219

[5] Yamada J,Toyoda H,Luhmann HJ.Cl- uptake promoting depolarizing GABA actions in immature rat neocortical neurones is mediated by NKCC1.J Physiol2004;557:829-41 PMCID:PMC1665166

[6] Watanabe M.Development and regulation of chloride homeostasis in the central nervous system.Front Cell Neurosci2015;9:371 PMCID:PMC4585146

[7] Luhmann HJ,Sinning A.Early GABAergic circuitry in the cerebral cortex.Curr Opin Neurobiol2014;26:72-8

[8] Chabrol FP,Sernagor E.GABAergic control of retinal ganglion cell dendritic development.Neurosci2012;227:30-43

[9] Zhang RW,Xia YM.Development of light response and GABAergic excitation-to-inhibition switch in zebrafish retinal ganglion cells.J Physiol2010;588:2557-69 PMCID:PMC2916988

[10] Ben-Ari Y,Reiffenstein RJ.Inhibitory conductance changes and action of gamma-aminobutyrate in rat hippocampus.Neurosci1981;6:2445-63

[11] Ben-Ari Y,Tyzio R.GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations.Physiol Rev2007;87:1215-84

[12] Leinekugel X,Khalilov I,Khazipov R.Ca²⁺ oscillations mediated by the synergistic excitatory actions of GABA_A and NMDA receptors in the neonatal hippocampus.Neuron1997;18:243-55

[13] Ben-Ari Y,Leinekugel X,Gaiarsa JL.GABAA, NMDA and AMPA receptors: a developmentally regulated 'ménage à trois'.Trends Neurosci1997;20:523-9

[14] Heck N,Reiprich P.GABA-A receptors regulate neocortical neuronal migration in vitro and in vivo.Cereb Cortex2007;17:138-48.

[15] Inada H,Uchida T.GABA regulates the multidirectional tangential migration of GABAergic interneurons in living neonatal mice.PLoS One2011;6:e27048 PMCID:PMC3236753

[16] Kirischuk S,Blanquie O,Luhmann HJ.Modulation of neocortical development by early neuronal activity: physiology and pathophysiology.Front Cell Neurosci2017;11:379 PMCID:PMC5712676

[17] Griguoli M.Early correlated network activity in the hippocampus: its putative role in shaping neuronal circuits.Front Cell Neurosci2017;11:255. PMCID:PMC5572250

[18] Kasyanov AM,Voronin LL.GABA-mediated giant depolarizing potentials as coincidence detectors for enhancing synaptic efficacy in the developing hippocampus.Proc Natl Acad Sci U S A2004;101:3967-72 PMCID:PMC374353

[19] Rivera C,Payne JA.The K⁺/Cl^- co-transporter KCC2 renders GABA hyperpolarizing during neuronal maturation.Nature1999;397:251-5

[20] Khalilov I,Chudotvorova I.Enhanced synaptic activity and epileptiform events in the embryonic KCC2 deficient hippocampus.Front Cell Neurosci2011;5:23 PMCID:PMC3206525

[21] Wang DD.Blocking early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits.Cereb Cortex2011;21:574-87 PMCID:PMC3041010

[22] Zheng JJ,Zhou ZJ.A developmental switch in the excitability and function of the starburst network in the mammalian retina.Neuron2004;44:851-64

[23] Spitzer NC.Neurotransmitter switching in the developing and adult brain.Annu Rev Neurosci2017;40:1-19

[24] Moody WJ.Ion channel development, spontaneous activity, and activity-dependent development in nerve and muscle cells.Physiol Rev2005;85:883-941.

[25] Dehorter N,Hammond C.Timing of developmental sequences in different brain structures: physiological and pathological implications.Eur J Neurosci2012;35:1846-56

[26] Ben-Ari Y.Neuro-archaeology: pre-symptomatic architecture and signature of neurological disorders.Trends Neurosci2008;31:626-36

[27] Cohen I,Clemenceau S,Miles R.On the origin of interictal activity in human temporal lobe epilepsy in vitro.Science2002;298:1418-21.

[28] Ben-Ari Y.NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disorders.Trends Neurosci2017;40:536-54

[29] Lozovaya N,Cloarec R.GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease.Nat Commun2018;9:1422 PMCID:PMC5897332

[30] Thompson EG.A role for ion channels in perivascular glioma invasion.Eur Biophys J2016;45:635-48 PMCID:PMC5347982

[31] Garzon-Muvdi T,ap Rhys C.Regulation of brain tumor dispersal by NKCC1 through a novel role in focal adhesion regulation.PLoS Biol2012;10:e1001320 PMCID:PMC3341330

[32] Damier P,Ben-Ari Y.Bumetanide to treat parkinson disease: a report of 4 cases.Clin Neuropharmacol2016;39:57-9

[33] Gagnon M,Lavertu G.Chloride extrusion enhancers as novel therapeutics for neurological diseases.Nat Med2013;19:1524-8 PMCID:PMC4005788

[34] Savardi A,De Vivo M.Pharmacological tools to target NKCC1 in brain disorders.Trends Pharmacol Sci2021;42:1009-34

[35] Capsoni S,Malerba F,Cattaneo A.Targeting the cation-chloride co-transporter NKCC1 to re-establish GABAergic inhibition and an appropriate excitatory/inhibitory balance in selective neuronal circuits: a novel approach for the treatment of Alzheimer's disease.Brain Sci2022;12:783 PMCID:PMC9221351

[36] Oberbauer R,Turnheim K.Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly.Clin Pharmacol Ther1995;57:42-51.

[37] Flamenbaum W.Pharmacology, therapeutic efficacy, and adverse effects of bumetanide, a new "loop" diuretic.Pharmacotherapy1982;2:213-22.

[38] Pressler RM,Marlow N.NEonatal seizure treatment with Medication Off-patent (NEMO) consortiumBumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial.Lancet Neurol2015;14:469-77.

[39] Ben-Ari Y.Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details.Epilepsia2021;62:935-40 PMCID:PMC8035263

[40] Löscher W.Reply to the commentary by Ben-Ari and delpire: bumetanide and neonatal seizures: fiction versus reality.Epilepsia2021;62:941-6

[41] Delpire E.A wholistic view of how bumetanide attenuates autism spectrum disorders.Cells2022;11:2419 PMCID:PMC9367773

[42] Lemonnier E,Phelep M.A randomised controlled trial of bumetanide in the treatment of autism in children.Transl Psychiatry2012;2:e202 PMCID:PMC3565189

[43] Lemonnier E.The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects.Acta Paediatr2010;99:1885-8

[44] Lemonnier E,Sonie S.Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.Transl sych2017;7:e1056 PMCID:PMC5416661

[45] Li Q,Shan H.The immuno-behavioural covariation associated with the treatment response to bumetanide in young children with autism spectrum disorder.Transl sych2022;12:228 PMCID:PMC9166783

[46] Dai Y,Yu J.Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial.Sci Bull2021;66:1591-8

[47] Fernell E,Gillberg C.Bumetanide for autism: open-label trial in six children.Acta Paediatr2021;110:1548-53 PMCID:PMC8248373

[48] Du L,Wang B.A pilot study on the combination of applied behavior analysis and bumetanide treatment for children with autism.J Child Adolesc Psychopharmacol2015;25:585-8

[49] Shaker E,Salamah A.Bumetanide, a diuretic that can help children with autism spectrum disorder.CNS Neurol Disord Drug Targets2023;23:536-42

[50] Sprengers JJ,Zuithoff NPA.Bumetanide for core symptoms of autism spectrum disorder (BAMBI): a single center, double-blinded, participant-randomized, placebo-controlled, phase-2 superiority trial.J Am Acad Child Adolesc Psychiatry2021;60:865-76

[51] van Andel DM, Sprengers JJ, Oranje B, Scheepers FE, Jansen FE, Bruining H. Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study.Mol Autism2020;11:30 PMCID:PMC7204231

[52] Hadjikhani N,Rogier O.Improving emotional face perception in autism with diuretic bumetanide: a proof-of-concept behavioral and functional brain imaging pilot study.Autism2015;19:149-57

[53] Hadjikhani N,Zürcher NR.Look me in the eyes: constraining gaze in the eye-region provokes abnormally high subcortical activation in autism.Sci Rep2017;7:3163 PMCID:PMC5466661

[54] Hadjikhani N,Lassalle A.Bumetanide for autism: more eye contact, less amygdala activation.Sci Rep2018;8:3602 PMCID:PMC5827728

[55] Crutel V,Penelaud PF.Bumetanide oral liquid formulation for the treatment of children and adolescents with autism spectrum disorder: design of two phase III studies (SIGN Trials).J Autism Dev Disord2021;51:2959-72 PMCID:PMC8254707

[56] Fuentes J,Georgoula C.Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: results from two randomized phase III studies.Autism Res2023;16:2021-34

[57] Tobe R,Gleissl T.Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder.Neuropsychopharmacol2023;48:1201-16 PMCID:PMC10267133

[58] Juarez-Martinez EL,Cristian G.Prediction of behavioral improvement through resting-state electroencephalography and clinical severity in a randomized controlled trial testing bumetanide in autism spectrum disorder.Biol Psychiatry Cogn Neurosci Neuroimaging2023;8:251-61.

[59] Masi A,Glozier N,Guastella AJ.Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis.Transl sych2015;5:e640 PMCID:PMC5068810